JP2017533698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533698A5 JP2017533698A5 JP2017519573A JP2017519573A JP2017533698A5 JP 2017533698 A5 JP2017533698 A5 JP 2017533698A5 JP 2017519573 A JP2017519573 A JP 2017519573A JP 2017519573 A JP2017519573 A JP 2017519573A JP 2017533698 A5 JP2017533698 A5 JP 2017533698A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- acid residues
- seq
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008874 T cell receptors Proteins 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims 52
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 5
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 claims 3
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 claims 3
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 claims 3
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 108010059255 MAGE-A10 antigen Proteins 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 1
- 108010075704 HLA-A Antigens Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061248P | 2014-10-08 | 2014-10-08 | |
| GB1417803.2 | 2014-10-08 | ||
| GBGB1417803.2A GB201417803D0 (en) | 2014-10-08 | 2014-10-08 | T cell receptors |
| US62/061,248 | 2014-10-08 | ||
| PCT/GB2015/052938 WO2016055785A1 (en) | 2014-10-08 | 2015-10-08 | T cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020070831A Division JP2020127406A (ja) | 2014-10-08 | 2020-04-10 | Ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533698A JP2017533698A (ja) | 2017-11-16 |
| JP2017533698A5 true JP2017533698A5 (enExample) | 2019-04-11 |
| JP6751391B2 JP6751391B2 (ja) | 2020-09-02 |
Family
ID=51947049
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017519573A Expired - Fee Related JP6751391B2 (ja) | 2014-10-08 | 2015-10-08 | Ｔ細胞受容体 |
| JP2020070831A Ceased JP2020127406A (ja) | 2014-10-08 | 2020-04-10 | Ｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020070831A Ceased JP2020127406A (ja) | 2014-10-08 | 2020-04-10 | Ｔ細胞受容体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11203627B2 (enExample) |
| EP (1) | EP3204409A1 (enExample) |
| JP (2) | JP6751391B2 (enExample) |
| KR (1) | KR20170092535A (enExample) |
| CN (1) | CN107001443A (enExample) |
| AU (2) | AU2015329783A1 (enExample) |
| BR (1) | BR112017007202A2 (enExample) |
| CA (1) | CA2963332A1 (enExample) |
| GB (1) | GB201417803D0 (enExample) |
| IL (1) | IL251524B (enExample) |
| MX (1) | MX2017004559A (enExample) |
| NZ (1) | NZ731571A (enExample) |
| RU (1) | RU2017115932A (enExample) |
| SG (1) | SG11201701983WA (enExample) |
| WO (1) | WO2016055785A1 (enExample) |
| ZA (1) | ZA201701823B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417803D0 (en) * | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
| KR102523449B1 (ko) | 2016-04-08 | 2023-04-19 | 어댑티뮨 리미티드 | T 세포 수용체 |
| GB201616238D0 (en) * | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| MA50188A (fr) | 2017-09-22 | 2021-06-02 | Wuxi Biologics Ireland Ltd | Nouveaux complexes polypeptidiques bispécifiques |
| EP3692063A1 (en) | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| CN109879957B (zh) * | 2017-12-06 | 2022-03-18 | 香雪生命科学技术（广东）有限公司 | 针对prame的高亲和力t细胞受体 |
| EP3775238A1 (en) * | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| WO2020156405A1 (en) * | 2019-01-28 | 2020-08-06 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel bispecific cd3/cd20 polypeptide complexes |
| GB201904328D0 (en) * | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| AU2020301161B2 (en) | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| EP3997116A1 (en) * | 2019-07-09 | 2022-05-18 | Medigene Immunotherapies GmbH | Magea10 specific t cell receptors and their use |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| WO2022022696A1 (zh) * | 2020-07-30 | 2022-02-03 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的高亲和力tcr |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240100162A1 (en) * | 2020-12-22 | 2024-03-28 | Amgen Inc. | Mage-b2-specific t-cell receptors |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954B2 (en) | 2021-10-29 | 2026-04-23 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982B2 (en) | 2021-12-22 | 2026-04-16 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN117003855B (zh) * | 2023-09-20 | 2024-02-23 | 广州市老人院 | 一种t细胞受体及其应用 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2026089992A1 (en) | 2024-10-21 | 2026-04-30 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN121779537A (zh) * | 2026-03-06 | 2026-04-03 | 北京立康生命科技有限公司 | 一种针对mage肽的特异性t细胞受体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0511124D0 (en) * | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| JP2007032255A (ja) | 2005-06-24 | 2007-02-08 | Tokai Rika Co Ltd | 車両用信号発信装置 |
| CN101287831B (zh) * | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| SG177025A1 (en) * | 2010-06-21 | 2012-01-30 | Agency Science Tech & Res | Hepatitis b virus specific antibody and uses thereof |
| CN103097407A (zh) * | 2010-07-28 | 2013-05-08 | 英美偌科有限公司 | T细胞受体 |
| AU2011304728A1 (en) * | 2010-09-20 | 2013-03-14 | Biontech Ag | Antigen-specific T cell receptors and T cell epitopes |
| CA2822938A1 (en) | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A polypeptide that binds aberrant cells and induces apoptosis |
| CA3114877C (en) * | 2011-09-15 | 2023-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| WO2013057586A1 (en) * | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| HK1212237A1 (en) * | 2012-08-31 | 2016-06-10 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| HUE050390T2 (hu) * | 2013-01-29 | 2020-11-30 | Max Delbrueck Centrum Fuer Molekulare Medizin Mdc | MAGE-A 1-t felismerõ nagy aviditású kötõ molekulák |
| GB201417803D0 (en) * | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
| EP3519433A1 (en) * | 2016-10-03 | 2019-08-07 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
-
2014
- 2014-10-08 GB GBGB1417803.2A patent/GB201417803D0/en not_active Ceased
-
2015
- 2015-10-08 WO PCT/GB2015/052938 patent/WO2016055785A1/en not_active Ceased
- 2015-10-08 JP JP2017519573A patent/JP6751391B2/ja not_active Expired - Fee Related
- 2015-10-08 CN CN201580054549.1A patent/CN107001443A/zh active Pending
- 2015-10-08 EP EP15782040.8A patent/EP3204409A1/en not_active Ceased
- 2015-10-08 SG SG11201701983WA patent/SG11201701983WA/en unknown
- 2015-10-08 CA CA2963332A patent/CA2963332A1/en not_active Abandoned
- 2015-10-08 MX MX2017004559A patent/MX2017004559A/es unknown
- 2015-10-08 RU RU2017115932A patent/RU2017115932A/ru unknown
- 2015-10-08 KR KR1020177012435A patent/KR20170092535A/ko not_active Ceased
- 2015-10-08 AU AU2015329783A patent/AU2015329783A1/en not_active Abandoned
- 2015-10-08 NZ NZ731571A patent/NZ731571A/en not_active IP Right Cessation
- 2015-10-08 BR BR112017007202-5A patent/BR112017007202A2/pt not_active IP Right Cessation
-
2017
- 2017-03-14 ZA ZA2017/01823A patent/ZA201701823B/en unknown
- 2017-04-03 IL IL251524A patent/IL251524B/en unknown
- 2017-04-05 US US15/480,103 patent/US11203627B2/en not_active Expired - Fee Related
-
2020
- 2020-04-10 JP JP2020070831A patent/JP2020127406A/ja not_active Ceased
- 2020-05-15 AU AU2020203201A patent/AU2020203201A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020127406A5 (enExample) | ||
| RU2017115932A (ru) | T-клеточные рецепторы | |
| JP6956164B2 (ja) | Ｔ細胞レセプター | |
| RU2762255C2 (ru) | Т-клеточные рецепторы | |
| RU2018138837A (ru) | Т-клеточные рецепторы | |
| RU2018138836A (ru) | Т-клеточные рецепторы | |
| ES2923026T3 (es) | Receptores de células T específicos para el complejo antígeno tumoral NY-ESO-1-HLA-A*02 | |
| JP2023081949A (ja) | Ｔ細胞受容体 | |
| MX2010002002A (es) | Peptido foxm1 y agente medicinal que lo contiene. | |
| HRP20220865T1 (hr) | T stanični receptori | |
| UA117216C2 (uk) | Пухлиноасоційований пептид та його застосування | |
| HRP20231645T1 (hr) | T stanični receptori | |
| JP2019517790A5 (enExample) | ||
| JP2019515653A5 (enExample) | ||
| US10316087B2 (en) | Soluble and stable heterodimeric TCR | |
| NZ708990A (en) | Method for activating helper t cell | |
| IL314832A (en) | Hiv-specific binding molecules and tcr | |
| BR112013013158B1 (pt) | composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso | |
| JP2022526786A (ja) | Ｈｂｖエンベロープタンパク質に特異的な結合性分子 | |
| RU2825837C2 (ru) | Специфичные связывающие молекулы | |
| KR20250151414A (ko) | 텔로머라제 역전사효소(tert) 양성 종양에 대한 백신 | |
| RU2022116808A (ru) | Т-клеточные рецепторы |